UY39633A - Materiales y métodos para direccionamiento mejorado de enlazadores - Google Patents

Materiales y métodos para direccionamiento mejorado de enlazadores

Info

Publication number
UY39633A
UY39633A UY0001039633A UY39633A UY39633A UY 39633 A UY39633 A UY 39633A UY 0001039633 A UY0001039633 A UY 0001039633A UY 39633 A UY39633 A UY 39633A UY 39633 A UY39633 A UY 39633A
Authority
UY
Uruguay
Prior art keywords
methods
addressing
materials
improved linker
antibodies
Prior art date
Application number
UY0001039633A
Other languages
English (en)
Inventor
Rajkumar Ganesan
Sanjaya Singh
Iqbal S Grewal
Jun Chen
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of UY39633A publication Critical patent/UY39633A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Moléculas que incluyen anticuerpos y fragmentos de unión a antígenos del mismo que se unen específicamente con un péptido enlazador y métodos de producción y uso de los anticuerpos y fragmentos de unión a antígenos se presentan en el presente documento. También se presentan en el presente documento métodos de generación de anticuerpos que se unen específicamente con un epítopo inmunorrecesivo.
UY0001039633A 2021-02-16 2022-02-16 Materiales y métodos para direccionamiento mejorado de enlazadores UY39633A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163149857P 2021-02-16 2021-02-16
US202163149883P 2021-02-16 2021-02-16
US202163149865P 2021-02-16 2021-02-16
US202163149892P 2021-02-16 2021-02-16
US202163149872P 2021-02-16 2021-02-16

Publications (1)

Publication Number Publication Date
UY39633A true UY39633A (es) 2022-08-31

Family

ID=80819664

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001039633A UY39633A (es) 2021-02-16 2022-02-16 Materiales y métodos para direccionamiento mejorado de enlazadores

Country Status (11)

Country Link
US (2) US11639396B2 (es)
EP (1) EP4294430A1 (es)
JP (1) JP2024506694A (es)
KR (1) KR20230145423A (es)
AU (1) AU2022224508A1 (es)
BR (1) BR112023016360A2 (es)
CA (1) CA3211114A1 (es)
MX (1) MX2023009568A (es)
TW (1) TW202246356A (es)
UY (1) UY39633A (es)
WO (1) WO2022177902A1 (es)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
CA2398136A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
JP4794301B2 (ja) 2003-06-11 2011-10-19 中外製薬株式会社 抗体の製造方法
AU2005282700A1 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
TWI671403B (zh) 2005-03-31 2019-09-11 中外製藥股份有限公司 控制組裝之多肽的製造方法
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
EP1973576B1 (en) 2005-11-28 2019-05-15 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
WO2007147901A1 (en) 2006-06-22 2007-12-27 Novo Nordisk A/S Production of bispecific antibodies
AU2008234248C1 (en) 2007-03-29 2015-01-22 Genmab A/S Bispecific antibodies and methods for production thereof
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
RS55218B1 (sr) 2008-10-31 2017-02-28 Janssen Biotech Inc Kompozicije fibronektin tip iii skalno baziranih domena, metode i upotrebe
JP5873335B2 (ja) 2009-02-12 2016-03-01 ヤンセン バイオテツク，インコーポレーテツド フィブロネクチンｉｉｉ型ドメインに基づくスカフォールド組成物、方法及び使用
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
MX353144B (es) 2010-04-20 2017-12-20 Genmab As Proteinas que contienen fc de anticuerpos heterodimericos y metodos para produccion de las mismas.
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
CN103429620B (zh) 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
PT2773671T (pt) 2011-11-04 2021-12-14 Zymeworks Inc Geração de anticorpo heterodimérico estável com mutações no domínio fc
TW202118792A (zh) * 2019-07-26 2021-05-16 美商健生生物科技公司 抗hk2嵌合抗原受體(car)

Also Published As

Publication number Publication date
WO2022177902A1 (en) 2022-08-25
US20230374156A1 (en) 2023-11-23
MX2023009568A (es) 2023-10-24
CA3211114A1 (en) 2022-08-25
EP4294430A1 (en) 2023-12-27
AU2022224508A1 (en) 2023-10-05
KR20230145423A (ko) 2023-10-17
US20220267472A1 (en) 2022-08-25
JP2024506694A (ja) 2024-02-14
US11639396B2 (en) 2023-05-02
TW202246356A (zh) 2022-12-01
BR112023016360A2 (pt) 2024-01-23

Similar Documents

Publication Publication Date Title
PE20201341A1 (es) Anticuerpos de union a gprc5d
CL2018002490A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123. (divisional solicitud 201701866)
PE20210460A1 (es) Anticuerpos especificos para cd47 y pdl1
CL2020003416A1 (es) Constructos de anticuerpo biespecificos que se unen a mesotelina y cd3 (divisional sol. 201800268)
CO2019009076A2 (es) Anticuerpos biespecíficos de unión específica a pd1 y lag3
UY37928A (es) Anticuerpos anti-cd38 y métodos de uso
PE20181013A1 (es) Constructos de anticuerpo biespecificos que se unen a egfrviii y cd3
CL2016002547A1 (es) Anticuerpos contra her2 biespecíficos
AR076018A1 (es) Anticuerpos multiespecificos especialmente biespecificos
CU24533B1 (es) Anticuerpos o fragmentos de los mismos que se unen a linfopoyetina estromal tímica (tslp) y composiciones farmacéuticas de los mismos
CL2019002894A1 (es) Anticuerpo monoclonal para pd-l1.
ECSP19035482A (es) Anticuerpo biespecífico heterodimérico estructural de anticuerpo natural anti-pd-1/anti-her2 y método para preparar el mismo
CO2019003759A2 (es) Anticuerpos que se unen a la proteína de envoltura del virus zika y usos de los mismos
CO2022007924A2 (es) Conjugados de anticuerpo y fármaco de eribulina anti-mesotelina y métodos de uso
PE20201149A1 (es) Anticuerpos de union a hla-a2/wt1
PE20181199A1 (es) Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
CO2021000386A2 (es) Anticuerpos humanizados contra psma
CO2022001021A2 (es) Anticuerpos que se unen a células cancerosas yque dirigen radionucleidos a dichas células
UY39633A (es) Materiales y métodos para direccionamiento mejorado de enlazadores
ECSP23001118A (es) Anticuerpos anti-betacelulina, fragmentos de los mismos, y moléculas de unión multiespecíficas
MX2020011844A (es) Anticuerpos bispecificos con marcadores con emparejamiento de cargas c-terminales escindibles.
CL2021001104A1 (es) Anticuerpo monoclonal que se une específicamente al antígeno cd20
AR124879A1 (es) Materiales y métodos para el direccionamiento mejorado de enlazadores
CO2022000404A2 (es) Fragmentos de unión a antígeno egfr y composiciones que los comprenden